How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

366 results for

Uric Acid Nephrolithiasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Comparison of potential dietary and urinary risk factors for ammonium urate nephrolithiasis in two bottlenose dolphin (Tursiops truncatus) populations. (PubMed)

biomarkers after a large meal. Urinary biomarkers and nephrolithiasis presence were assessed opportunistically in 15 long-term resident free-ranging dolphins living in Sarasota Bay, Florida. Additionally, the total purine contents of fish commonly consumed by each dolphin population were measured to evaluate potential dietary risk factors. Populations were compared for total dietary purine composition, recently fed status, nephrolithiasis presence, and differences in urinary biochemical, acid-base (...) , and physicochemical parameters via Wilcoxon rank sum analysis and least square means. Managed dolphins had higher urinary pH and ammonium ([Formula: see text]) in both pre- and postprandial conditions and higher urinary uric acid and saturation indices of NH4U in the postprandial condition compared with free-ranging dolphins ( P < 0.05). The purine content was greater ( P < 0.0001) in the diet consumed by managed dolphins [7 mmol/Mcal metabolizable energy (ME)] than in the free-ranging dolphin diet (4 mmol/Mcal

2018 American Journal of Physiology. Renal physiology

22. Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis

one year prior to randomisation or gout arthritis requiring uric acid lowering therapy Cystinuria at screening Hypokalemia (blood potassium level < 3 mmol/L) at screening Hyponatremia (blood sodium level < 125 mmol/L) at screening Pregnant and lactating women [pregnancy test to be performed for women of child-bearing potential (defined as women who are not surgically sterilized/ hysterectomized, and/ or who are postmenopausal for less than 12 months)] Previous (within 3 months prior (...) Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2017 Clinical Trials

23. Association Between Sonographically Diagnosed Nephrolithiasis and Subclinical Coronary Artery Calcification in Adults. (PubMed)

of screening examination, physical activity, alcohol intake, smoking status, education level, body mass index, family history of cardiovascular disease, total energy intake, glucose concentration, systolic blood pressure, triglyceride concentration, high-density lipoprotein cholesterol concentration, uric acid concentration, and estimated glomerular filtration rate, the CAC score ratio was attenuated, but remained significant (CAC score ratio, 1.31; 95% CI, 1.00-1.71).Computed tomographic diagnosis (...) Association Between Sonographically Diagnosed Nephrolithiasis and Subclinical Coronary Artery Calcification in Adults. Although recent studies suggest an association between nephrolithiasis and clinical cardiovascular events, this association has been underexplored.Cross-sectional study.62,091 asymptomatic adults without known coronary heart disease who underwent a screening health examination that included cardiac tomography.Nephrolithiasis.Coronary artery calcification (CAC).Nephrolithiasis

2017 American Journal of Kidney Diseases

24. Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis. (PubMed)

and nephrolithiasis or renal/kidney stones have been suggested to be a common manifestation of disease in forms of uric acid, calcium phosphate or calcium oxalate. We performed a meta-analysis on five clinical trials and reported that correlation between IBD and formation of stone in renal system is positive and significant (Fix-effect model; CI: 95%, P <0.001, and randomeffect model; CI: 95%, P = 0.03).Based on the reports of the clinical trials, calcium oxalate is more prevalent in Crohn's disease (CD) than (...) Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis. The extra-intestinal manifestations of inflammatory bowel disease (IBD) are common and involve other organs or systems for example; urinary system.For this review, we used a variety of sources by searching through Web of Science, PubMed, EMBASE, Scopus and directory of open access journals (DOAJ).Urinary complications may occur in up to 22% of patients

Full Text available with Trip Pro

2017 Journal of nephropathology

25. MKSAP: 28-year-old man is evaluated for recurrent nephrolithiasis

), blood pressure is 131/78 mm Hg, pulse rate is 84/min, and respiration rate is 12/min. BMI is 22. The abdominal examination shows healed surgical incisions and is otherwise unremarkable. The remainder of the examination is normal. Laboratory studies, including complete blood count, electrolytes, and kidney function, are normal. Urinalysis is normal; 24-hour urine chemical analysis shows normal levels of calcium, citrate, and uric acid, but elevated oxalate. Plain abdominal radiographs show multiple (...) MKSAP: 28-year-old man is evaluated for recurrent nephrolithiasis Treatment for enteric hyperoxaluria and calcium oxalate nephrolithiasis MKSAP: 28-year-old man is evaluated for recurrent nephrolithiasis | | May 13, 2017 1 Shares Test your medicine knowledge with the , in partnership with the . A 28-year-old man is evaluated for recurrent nephrolithiasis. Medical history is significant for Crohn disease complicated by multiple small bowel strictures requiring resection. He began developing

2017 KevinMD blog

26. Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. (PubMed)

Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. Although the association between gout and nephrolithiasis is well known, the relationship between asymptomatic hyperuricemia and the development of nephrolithiasis is largely unknown.Cohort study.239,331 Korean adults who underwent a health checkup examination during January 2002 to December 2014 and were followed up annually or biennially through December 2014.Baseline serum uric acid levels of participants.The (...) development of nephrolithiasis during follow-up.Nephrolithiasis is determined based on ultrasonographic findings. A parametric Cox model was used to estimate the adjusted HRs of nephrolithiasis according to serum uric acid level.During 1,184,653.8 person-years of follow-up, 18,777 participants developed nephrolithiasis (incidence rate, 1.6/100 person-years). Elevated uric acid level was significantly associated with increased risk for nephrolithiasis in a dose-response manner (P for trend < 0.001) in men

2017 American Journal of Kidney Diseases

27. Etiopathogenesis of Nephrolithiasis in Ulcerative Colitis Patients with the Ileal Pouch Anal Anastomosis. (PubMed)

and no nephrolithiasis.Using cross-sectional study design, serum and 24-hour urine metabolic compositions were compared between IPAA patients with nephrolithiasis (the study group) and those without (the control group). Urinary supersaturation of calcium oxalate, calcium phosphate, and uric acid was calculated.A total of 40 patients were enrolled in the study. There were no significant differences in serum electrolytes, vitamin D, parathyroid hormone, and kidney function tests between the study (n = 20) and control groups (...) Etiopathogenesis of Nephrolithiasis in Ulcerative Colitis Patients with the Ileal Pouch Anal Anastomosis. Our previous study showed that nephrolithiasis is a common complication in ulcerative colitis patients after ileal pouch anal anastomosis (IPAA). However, the pathogenesis of nephrolithiasis in IPAA patients has not been studied. The aim of this study was to compare urine and serum metabolic compositions in IPAA patients with nephrolithiasis and controls with IPAA

2017 Inflammatory Bowel Diseases

28. Multiple Sclerosis and Nephrolithiasis: A Matched Case Comparative Study. (PubMed)

nephrolithotomy (PCNL; 25% vs 12%, P = 0.005) or a cystolithopaxy (16% vs 3%, P < 0.001) compared to their matched controls. In all, 61 patients had a complete 24-h urinary stone panel. There were no significant differences in urinary pH, volume, creatinine, calcium, citrate, oxalate, sodium, and uric acid as well as rates of hypocitraturia, hyperoxaluria, hypercalciuria, and hyperuricosuria among patients with MS. Use of intermittent straight catheterisation [ISC; odds ratio (OR) 3.50, 95% confidence (...) Multiple Sclerosis and Nephrolithiasis: A Matched Case Comparative Study. To compare stone composition and serum/urine biochemistries in stone formers with multiple sclerosis (MS) against stone formers without MS and to examine the association between mobility, methods of bladder emptying, and stone formation.In this retrospective case-control study, we identified patients diagnosed with MS and kidney stone disease who were seen at our institution between 2001 and 2016. For the first part

2017 BJU international

29. Mature Vinegar Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis

. Secondary Outcome Measures : 24-h urine compositions [ Time Frame: 3 years ] Change in 24-h urine compositions (calcium excretion, oxalate excretion, etc.) serum calcium [ Time Frame: 3 years ] Change in serum calcium serum creatinine [ Time Frame: 3 years ] Change in serum creatinine serum uric acid [ Time Frame: 3 years ] Change in serum uric acid Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk (...) calcium oxalate or mixed (calcium oxalate and phosphate, calcium oxalate and uric acid) stone formation over the last 5 years; the stone had been removed completely confirmed by CT scan; No current treatment for the prevention of recurrent stones except for the advice to increase water intake; Residence in the area of Guangzhou, China; Written informed consent Exclusion Criteria: Obstructive uropathy, chronic urosepsis, renal failure (serum creatinine > 177 umol/L), renal tubular acidosis, primary

2017 Clinical Trials

30. Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies

recurrent kidney stones, and whether stone composition and pre- and post-treatment biochemistries predict treatment efficacy. Authors' conclusions Increased fluid intake, reduced soft drink consumption, thiazide diuretics, citrate pharmacotherapy, and allopurinol reduce risk of recurrent calcium stones. Effects of other dietary interventions appear mixed. We identified no RCTs for uric acid or cystine stones. Data regarding whether baseline or followup biochemistries predict treatment efficacy (...) Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Monga M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA

2012 Health Technology Assessment (HTA) Database.

31. Might E-cadherin promoter polymorphisms of rs16260 and rs5030625 associate with the risk of nephrolithiasis? (PubMed)

(PCR-RLFP). Haplotype frequencies were also analyzed. To determine the association of rSNPs of CDH1 gene with the clinicopathological features of nephrolithiasis, nearly all possible etiological factors were documented. These factors were family history, gender, age, body mass index, liquid consumption, eating habits, tea-coffee and meat (oxalate rich) consumption, adequate physical activity, and all serum and urine levels-the serum levels of Na, K, Cl, phosphate, Ca, Mg, uric acid, albumin, blood (...) urea nitrogen (BUN), creatinine and serum parathyroid hormone (PTH) as well as 24 h urine excretions of creatinine, Na, K, Cl, phosphate, Ca, Mg, citrate, oxalate, uric acid, albumin and BUN.Significant differences were found between rs16260 and the risk of nephrolithiasis. Patients having CA genotype of rs16260 CDH1 polymorphism were associated with an almost trifold increased risk for developing kidney stone than those with the AA genotype (95 % CI 1.08-7.28, OR 2.8, P = 0.033). We also found

Full Text available with Trip Pro

2016 SpringerPlus

32. Nephrolithiasis in elderly population; effect of demographic characteristics (PubMed)

to be the case group and other subjects without a history of kidney stones served as control group. Demographic and anthropometric data, smoking, diabetes and metabolic syndrome (MetS), calcium (Ca), vitamin D, parathyroid hormone (PTH), uric acid and urine pH were compared in both groups.In this study, 1390 elderly people with the mean age of 69.37 ± 7.42 years were evaluated which 202 (14.53%) cases had renal stones. The patients with nephrolithiasis were younger (P = 0.010) and had higher uric acid (...) Nephrolithiasis in elderly population; effect of demographic characteristics Kidney stone (nephrolithiasis) is one of the most common diseases. During the past several decades, its prevalence and incidence have increased markedly in elderly population.This study was conducted to evaluate the risk factors for nephrolithiasis in elderly population.This study was based on the Amirkola Health and Ageing Project (AHAP). Elderly people with kidney stones in every size, type and number were considered

Full Text available with Trip Pro

2016 Journal of nephropathology

33. Significant differences in struvite and cystine stone frequency seen among Chinese nephrolithiasis patients living in North America compared to those living in China (PubMed)

rates of calcium-based and uric acid calculi as well as urinary pH were seen among both groups.Significant differences exist between Chinese nephrolithiasis patients living in China compared to those living in North America, highlighting the importance of environmental factors in addition to genetics in modulating risk for urinary stone disease. (...) Significant differences in struvite and cystine stone frequency seen among Chinese nephrolithiasis patients living in North America compared to those living in China Interracial disparities in nephrolithiasis prevalence have been reported, but the interplay between genetics and the environment for urinary stone disease risk factors is poorly understood. To examine how environment may alter genetic predisposition for stone formation, we established the International Chinese Consortium

Full Text available with Trip Pro

2016 Translational andrology and urology

34. Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation

Universitaire de Nice More Information Go to Layout table for additonal information Responsible Party: Centre Hospitalier Universitaire de Nice ClinicalTrials.gov Identifier: Other Study ID Numbers: 15-AOI-07 First Posted: September 28, 2015 Last Update Posted: March 12, 2018 Last Verified: March 2018 Keywords provided by Centre Hospitalier Universitaire de Nice: Renal Ammonium ;uric acid Additional relevant MeSH terms: Layout table for MeSH terms Overweight Nephrolithiasis Body Weight Signs and Symptoms (...) Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2015 Clinical Trials

35. Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86938/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) of Diabetes ECG electrocardiogram ECHA European Chemicals Agency eGFR estimated glomerular filtration rate ER excluding rescue ERA Environmental risk assessment ESI-MS electrospray positive ionization mass spectra FA Focus area FAS full analysis set FeCl 3 Iron (III) chloride Fpen Market penetration factor FPG fasting plasma glucose GAD glutamic acid decarboxylase GC gas chromatography GMP good manufacturing practice HCTZ hydrochlorothiazide HDL-C high-density lipoprotein-cholesterol HDPE high density

2018 European Medicines Agency - EPARs

36. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86928/2018 Committee for Medicinal Products for Human Use (...) Ertu/Met ertugliflozin/metformin Ertu/Met pool pooled safety data from placebo-controlled ertugliflozin add-on metformin phase III studies ESFA European Food Safety Authority ESI-MS electrospray positive ionization mass spectra FA Focus area FAS full analysis set Assessment report EMA/86928/2018 Page 5/159 FDA Food and Drug Administration FDC fixed-dose combination FeCl 3 Iron (III) chloride Fpen Market penetration factor FPG fasting plasma glucose GAD glutamic acid decarboxylase GC gas

2018 European Medicines Agency - EPARs

37. Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86941/2018 Committee for Medicinal Products (...) Concentration L-PGA L-pyroglutamic acid LS least-squares MACE major adverse cardiovascular event MAR missing at random MNAR missing-not-at-random assumption MCAR missing completely at random MedDRA Medical Dictionary for Regulatory Activities mFAS modified FAS NDA New Drug Application NIR near infrared NMR nuclear magnetic resonance NMT not more than NOEC No Observed Effect Concentration PA polyamide PAR proven acceptable ranges PAT process analytical technology PD pharmacodynamic(s) PDLC pre-defined limit

2018 European Medicines Agency - EPARs

38. Uric acid and the kidney. (PubMed)

acid levels. Gout is rare in children; yet its presence necessitates evaluation for enzymatic defects in purine metabolism. Well-known effects of uric acid on the kidney include nephrolithiasis and acute kidney injury (AKI) in the setting of tumor lysis. However, recent data suggest that uric acid may be an important factor in the pathogenesis of AKI in general, as well as of chronic kidney disease (CKD) and hypertension. Hence, uric acid may not only be a marker but also a potential therapeutic (...) Uric acid and the kidney. Uric acid, the end product of purine metabolism, is excreted predominantly by the proximal tubules. Abnormal serum levels of uric acid are due to alterations in production or excretion. Fractional excretion of uric acid is helpful in determining the underlying etiology of hypouricemia or hyperuricemia in children. Abnormalities in the molecular mechanisms that control renal uric acid tubular transport are implicated in various disorders associated with abnormal uric

2014 Pediatric Nephrology

39. Uric Acid Nephropathy (Diagnosis)

acid into the more soluble compound allantoin. Three forms of kidney disease have been attributed to excess uric acid: acute uric acid nephropathy, chronic urate nephropathy, and uric acid nephrolithiasis. These disorders share the common element of excess uric acid or urate deposition, although the clinical features vary. [ ] Next: Pathophysiology Properties of uric acid Uric acid, the product of the xanthine oxidase–catalyzed conversion of xanthine and hypoxanthine, is the final metabolite (...) ), a condition that is also known as Lesch-Nyhan syndrome. This is an X-linked disorder that results in mental retardation, involuntary movement, self-mutilation, gout, and early kidney failure. In these patients, chronic uric acid overproduction causes hyperuricemia and uricosuria. The incidence of chronic kidney disease is high in these individuals, who have intratubular uric acid deposits and interstitial urate deposits. Uric acid nephrolithiasis Uric acid stones, which represent 5-10% of all renal

2014 eMedicine.com

40. Uric Acid Nephropathy (Treatment)

of chronic nephropathy alone, although this topic remains under active study and debate. The significant toxicity of allopurinol and the lifelong expense of using it make this therapy unwarranted. The emphasis should be on controlling other risk factors for kidney failure, such as diabetes and hypertension. Uric acid nephrolithiasis The goals of uric acid nephrolithiasis therapy are to reduce the existing stone size and to prevent the formation of new stones. These objectives are achieved by decreasing (...) Uric Acid Nephropathy (Treatment) Uric Acid Nephropathy Treatment & Management: Medical Care Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjQ0MjU1LXRyZWF0bWVudA== processing > Uric Acid Nephropathy Treatment

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>